National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Doxylamine/pyridoxine (Xonvea®) is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

 

NCPE Assessment Process Complete
Rapid review commissioned 23/07/2019
Rapid review completed 15/08/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Xonvea®) not be considered for reimbursement at the submitted price*

 

* This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medial Goods) Act 2013.